The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation
Open Access
- 25 January 2024
- journal article
- research article
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (1) , 40-50
Abstract
The use of high-effective, multicomponent, risk-adopted chemoimmunotherapy schemes in children with Burkitt lymphoma reached advanced long-term progression-free survival over 90 % even for high risk patients. Unfortunately, conventional therapeutic strategy for relapsed/refractory disease is not accepted, and the effectiveness of carboplat‑in- and gemcitabine-containing regimens is unsatisfactory. Clinical experience of rituximab, ibrutinib and nivolumab in combination with polychemotherapy and own clinical case of successful relapsed Burkitt lymphoma treatment with targeted therapy and following autologous and allogeneic hematopoietic stem cell transplantation are presented. Proposed program could achieve a complete remission of Burkitt lymphoma, but short-term after allogeneic hematopoietic stem cell transplantation diagnosed T-cell precursor acute lymphoblastic leukemia became fatal for the patient.Keywords
This publication has 33 references indexed in Scilit:
- Relapsed/refractory pediatric B‐cell non‐Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study GroupPediatric Blood & Cancer, 2016
- Therapy for Burkitt’s lymphoma according to the BL-M-04 protocol: 12-year experienceTerapevticheskii arkhiv, 2015
- Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and AdolescentsCancer Research and Treatment, 2014
- Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantationPediatric Blood & Cancer, 2013
- Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemiaLeukemia & Lymphoma, 2012
- Donor Cell Leukemia: A ReviewTransplantation and Cellular Therapy, 2011
- A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B‐cell (CD20+) non‐Hodgkin lymphoma and mature B‐cell acute lymphoblastic leukemia: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2008
- The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B‐cell non‐Hodgkin lymphoma and mature B‐cell leukemia: A retrospective analysis of enrolled cases in JapanPediatric Blood & Cancer, 2008
- Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: A population-based analysis of the Austrian cooperative study groupPediatric Blood & Cancer, 2004
- Outcome of relapsed or refractory childhood B‐cell acute lymphoblastic leukaemia and B‐cell non‐Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocolsBritish Journal of Haematology, 2001